DONGWHA PHARM-Anti-allergic asthma drug(Pd No. : 3078679)

(Updated : Feb/03/2017)
product information
Model Nm KDDF-201512-03
HS CODE 300390
Keywords drug, asthma, dongwha, bio, medical
Seller ID itrade2000

Pre-clinical study & clinical IND approval for the development of antiallergic asthma drug

[Development and Market Objectives]

  DW2008 is a natural product that inhibits both allergic inflammation and bronchoconstriction, and is currently under nonclinical GLP study for developing anti-allergic asthma drug. We plan to test on the toxicity and additional efficacy of DW2008 for global licensingout, as well as for local launching.

[Unmet Medical Need & Target Patients]

 Target population

•  Asthmatic patients who are ranked at step2(Mild) ~ step5(Severe) of GINA guideline.

•  Asthmatic patients, especially old age patients and pediatric patients, who show poor medication compliance in inhalation therapy.

•  Asthmatic patients who are not improved with leukotriene receptor antagonists. •  Asthmatic patients who show steroid resistance.

  Unmet Needs

•  Inhalation Corticosteroids(ICS) are current 1’st line therapeutic drugs of asthma, which exert good anti-inflammatory activities. But, ICS also show lots of regional adverse effects, steroid phobia, poor medication compliance.

•  Bronchodilators temporarily relieve asthmatic symptoms as relievers. But, they rather have risk for an asthma exacerbation in case of long term treatment, because they have not anti-inflammatory activities. They are also inhalers that cause poor medication compliance.

•  Leukotrine receptor antagonists(LTRA) are oral asthmatic drugs with over 90% market share, and have good medication compliance. But, they are usually used as add-on therapy to ICS, due to their insufficient efficacy.

•  Whereas there are inhaler combination drugs “ICS+LARB”, there are no oral drugs with anti-allergic inflammatory effects and bronchodilation effects.


•  The candidate DW2008 is currently under GLP preclinical study according to OECD, ICH guideline in Korea •  The candidate DW2008 is currently under drug positioning study in 5 asthma subtype animal models and searching specific biomarkers for setting up optimal patient selection criteria. 

[Intellectual Property]

•  Patent pending: Korea (2) PCT(1)

•  Covering worldwide

[Competitive Advantages]

•Efficacy & MoA

-  Dual effects (anti-allergic inflammatory effect and bronchodilation effect)

-  Superior effects of DW2008 versus Montelukast(allergy inflammation) or Ambroxol(Mucosal Secretion)

-  Th2/Th17 selectivity

-  Identification of multiple targets relating to anti-allergic inflammation and bronchodilation


-  Well-controlled CMC

-  Using GAP(Good agriculture practice) certificated botanical material

-  Identification of over 80% components (in HPLC peak area)

•Compliance and Others

-  Better medical compliance than inhalation

-  Beyond indications to other allergic diseases or respiratory diseases, such as rhinitis, atopic dermatitis, and COPD.

Company Information

company information
Contact Person Sun Tae Hwang
Homepage www.dong-wha.co.kr , http://seller.buykorea.org/dongwha-pharm--1036300
Tel 0220219300 Fax 027784373
Biz. Type Est. Year
Employees Annual Export USD 0~1 mn
Related Business Event List
InCheon BIOplus GP Business Meeting 2017-09-13 ~ 2017-09-13
Global Bio Pharma Plaza(GBPP 2017) 2017-11-27 ~ 2017-11-28
Innovation & Technology Business Partnering 2017 COEX Intercontinental, Seoul, South Korea 2017-03-29 ~ 2017-03-30
CPhI World Wide 2016 2017-10-24 ~ 2017-10-26
InnoMedi 2017-03-29 ~ 2017-03-29
Go to the top of the page